
Chemotherapy Induced Peripheral Neuropathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Description
Chemotherapy Induced Peripheral Neuropathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chemotherapy Induced Peripheral Neuropathy - Drugs In Development, 2022, provides an overview of the Chemotherapy Induced Peripheral Neuropathy (Toxicology) pipeline landscape.
Chemotherapy-induced peripheral neuropathy (CIPN) is a side effect of cancer treatment. Symptoms include pain, burning, tingling, constipation, muscle weakness, blood pressure changes and balance problems. Risk factors include longer duration of therapy, pre-existing neuropathy and type of chemotherapeutic agent.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chemotherapy Induced Peripheral Neuropathy - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Chemotherapy Induced Peripheral Neuropathy (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Chemotherapy Induced Peripheral Neuropathy (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Chemotherapy Induced Peripheral Neuropathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 8, 13, 26 and 8 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.
Chemotherapy Induced Peripheral Neuropathy (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chemotherapy Induced Peripheral Neuropathy - Drugs In Development, 2022, provides an overview of the Chemotherapy Induced Peripheral Neuropathy (Toxicology) pipeline landscape.
Chemotherapy-induced peripheral neuropathy (CIPN) is a side effect of cancer treatment. Symptoms include pain, burning, tingling, constipation, muscle weakness, blood pressure changes and balance problems. Risk factors include longer duration of therapy, pre-existing neuropathy and type of chemotherapeutic agent.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chemotherapy Induced Peripheral Neuropathy - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Chemotherapy Induced Peripheral Neuropathy (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Chemotherapy Induced Peripheral Neuropathy (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Chemotherapy Induced Peripheral Neuropathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 8, 13, 26 and 8 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.
Chemotherapy Induced Peripheral Neuropathy (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Peripheral Neuropathy (Toxicology).
- The pipeline guide reviews pipeline therapeutics for Chemotherapy Induced Peripheral Neuropathy (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Chemotherapy Induced Peripheral Neuropathy (Toxicology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Chemotherapy Induced Peripheral Neuropathy (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Chemotherapy Induced Peripheral Neuropathy (Toxicology)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Chemotherapy Induced Peripheral Neuropathy (Toxicology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Chemotherapy Induced Peripheral Neuropathy (Toxicology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
165 Pages
- Introduction
- Global Markets Direct Report Coverage
- Chemotherapy Induced Peripheral Neuropathy – Overview
- Chemotherapy Induced Peripheral Neuropathy – Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Chemotherapy Induced Peripheral Neuropathy – Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Chemotherapy Induced Peripheral Neuropathy – Companies Involved in Therapeutics Development
- Abalone Bio Inc
- Achelios Therapeutics Inc
- Algenis
- Algo Therapeutix SAS
- Annji Pharmaceutical Co Ltd
- Apexian Pharmaceuticals Inc
- Aphios Corp
- Aptinyx Inc
- Asahi Kasei Pharma Corp
- Avantyx Pharmaceuticals LLC
- Bexion Pharmaceuticals LLC
- Bright Minds Biosciences Inc
- Bristol-Myers Squibb Co
- Candel Therapeutics Inc
- CSPC NBP Pharmaceutical Co Ltd
- Daiichi Sankyo Co Ltd
- Disarm Therapeutics Inc
- EA Pharma Co Ltd
- Egetis Therapeutics AB
- Enveric Biosciences Inc
- Exodos Life Sciences Limited Partnership
- Helsinn Group
- Hoba Therapeutics ApS
- Immune Pharmaceuticals Inc
- Kineta Inc
- Kyorin Pharmaceutical Co Ltd
- LTT Bio-Pharma Co Ltd
- MAKScientific LLC
- Medifron DBT Co Ltd
- Metys Pharmaceuticals AG
- Mundipharma International Ltd
- Nanjing Aimeifei Biomedical Technology Co Ltd
- NeurExo Sciences LLC
- Neuropathix Inc
- NeuroTherpia Inc
- OliPass Corporation
- Osmol Therapeutics Inc
- Oxford Cannabinoid Technologies Ltd
- PharmatrophiX Inc
- Regulonix LLC
- Resolute Pharma Inc
- Senzer Ltd
- SiteOne Therapeutics Inc
- Skye Bioscience Inc
- Sonnet BioTherapeutics Holdings Inc
- Sova Pharmaceuticals Inc
- Synerkine Pharma BV
- Trevena Inc
- WEX Pharmaceuticals Inc
- Winsantor Inc
- Xgene Pharmaceutical Inc
- Chemotherapy Induced Peripheral Neuropathy – Drug Profiles
- (amitriptyline + ketamine hydrochloride) – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- (cannabidiol + dronabinol) – Drug Profile
- Product Description
- Mechanism Of Action
- ACY-1083 – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- AJ-302 – Drug Profile
- Product Description
- Mechanism Of Action
- AM-1710 – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- amitriptyline – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- APH-1502 – Drug Profile
- Product Description
- Mechanism Of Action
- APH-1503 – Drug Profile
- Product Description
- Mechanism Of Action
- APX-2009 – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- APX-3330 – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- atexakin alfa – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Biologics for Chemotherapy Induced Peripheral Neuropathy – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- BR-297 – Drug Profile
- Product Description
- Mechanism Of Action
- butylphthalide – Drug Profile
- Product Description
- Mechanism Of Action
- BXQ-350 – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- calmangafodipir – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- cannabidiol – Drug Profile
- Product Description
- Mechanism Of Action
- Drug to Inhibit MMP-13 for Chemotherapy Induced Peripheral Neuropathy – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- EA-4017 – Drug Profile
- Product Description
- Mechanism Of Action
- HB-086 – Drug Profile
- Product Description
- Mechanism Of Action
- HM-01 – Drug Profile
- Product Description
- Mechanism Of Action
- ibudilast – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- IPG-006 – Drug Profile
- Product Description
- Mechanism Of Action
- KCP-506 – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- ketoprofen – Drug Profile
- Product Description
- Mechanism Of Action
- KLS-13019 – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- LM-11A31BHS – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- LT-1001 – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- mirogabalin besylate – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Monoclonal Antibodies to Agonize CB2 for Chemotherapy Induced Peripheral Neuropathy – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- MP-101 – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- MR-309 – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- NAVX-010 – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- NRX-2922 – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- NTRX-07 – Drug Profile
- Product Description
- Mechanism Of Action
- OCT-461201 – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- OLP-1002 – Drug Profile
- Product Description
- Mechanism Of Action
- OSM-0205 – Drug Profile
- Product Description
- Mechanism Of Action
- PGN-503 – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- pirenzepine – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- ricolinostat – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- RPI-002 – Drug Profile
- Product Description
- Mechanism Of Action
- SK-02 – Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecule for Algodystrophy, Chemotherapy Induced Peripheral Neuropathy, Diabetic Peripheral Neuropathy and Pain – Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecule to Agonize 5-HT2A and 5-HT2C for Pain – Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecule to Agonize CB1 and CB2 for Chemotherapy Induced Peripheral Neuropathy – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Small Molecule to Agonize MOR1 for Chemotherapy Induced Peripheral Neuropathy, Diabetic Peripheral Neuropathy and Postherpetic Neuralgia – Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecules to Block CaV2.2 for Chemotherapy Induced Peripheral Neuropathy – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Small Molecules to Block Nav 1.8 for Chemotherapy Induced Peripheral Neuropathy – Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecules to Inhibit NaV1.7 for Chemotherapy Induced Peripheral Neuropathy – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Small Molecules to Inhibit SARM1 for Neurology and Glaucoma – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- SV-250 – Drug Profile
- Product Description
- Mechanism Of Action
- Tetrodotoxin – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- thrombomodulin alfa – Drug Profile
- Product Description
- Mechanism Of Action
- TRV-045 – Drug Profile
- Product Description
- Mechanism Of Action
- UAWJ-111 – Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- XG-005 – Drug Profile
- Product Description
- Mechanism Of Action
- Chemotherapy Induced Peripheral Neuropathy – Dormant Projects
- Chemotherapy Induced Peripheral Neuropathy – Discontinued Products
- Chemotherapy Induced Peripheral Neuropathy – Product Development Milestones
- Featured News & Press Releases
- Mar 29, 2022: Asahi Kasei’s Recomodulin enters US-Japan PI study for chemotherapy-induced peripheral neuropathy
- Mar 08, 2022: Data from pre-clinical study of OCT461201 shows positive results
- Nov 17, 2021: AlgoTherapeutix completes phase I for peripheral neuropathy program ATX01, poised for phase II initiation in 2022
- May 13, 2021: Osmol Therapeutics initiates IND enabling studies to develop first therapy for prevention of chemotherapy-induced peripheral neuropathy
- May 06, 2021: Neuropathix announces publication of validated preclinical studies on KLS-13019 in the British Journal of Pharmacology
- Jan 25, 2021: Sonnet BioTherapeutics announces the successful completion of a non-human primate toxicology study of SON-080
- Dec 15, 2020: AlgoTherapeutix receives regulatory approval to initiate clinical development of ATX01
- Dec 10, 2020: Trevena announces presentations highlighting novel S1P1 receptor modulator at the American College of Neuropsychopharmacology 59th annual meeting
- Sep 24, 2020: MediciNova announces positive clinical results regarding MN-166 (ibudilast) for prevention of chemotherapy-induced peripheral neuropathy published in Cancer Chemotherapy and Pharmacology
- Mar 03, 2020: Kannalife receives patent in the European Union (EU) for its novel monotherapeutic compound to treat CNS and PNS disorders
- Feb 13, 2020: Medical Marijuana portfolio investment company Kannalife announces completion of NIH-NIDA phase 1 grant and results from Temple University
- Jan 28, 2020: Kannalife CEO recaps 2019 advances and potential ahead
- Jan 14, 2020: Kannalife further elucidates mechanism of action behind KLS-13019, the company’s leading drug candidate for the potential treatment of neuropathic pain
- Dec 11, 2019: Kannalife announces filing of U.S. Patent 62/934,861 - Functionalized 1, 3 Benzene Diols and their method of use for the treatment of radiation dermatitis and other skin disorders
- Oct 22, 2019: Disarm Therapeutics reports preclinical data demonstrating small molecule SARM1 inhibitors preserve both axonal structure and function in vitro and in vivo
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Table 1: Number of Products under Development for Chemotherapy Induced Peripheral Neuropathy, 2022
- Table 2: Number of Products under Development by Companies, 2022
- Table 3: Number of Products under Development by Companies, 2022 (Contd..1)
- Table 4: Number of Products under Development by Companies, 2022 (Contd..2)
- Table 5: Number of Products under Development by Universities/Institutes, 2022
- Table 6: Products under Development by Companies, 2022
- Table 7: Products under Development by Companies, 2022 (Contd..1)
- Table 8: Products under Development by Companies, 2022 (Contd..2)
- Table 9: Products under Development by Universities/Institutes, 2022
- Table 10: Number of Products by Stage and Target, 2022
- Table 11: Number of Products by Stage and Target, 2022 (Contd..1)
- Table 12: Number of Products by Stage and Mechanism of Action, 2022
- Table 13: Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)
- Table 14: Number of Products by Stage and Route of Administration, 2022
- Table 15: Number of Products by Stage and Molecule Type, 2022
- Table 16: Chemotherapy Induced Peripheral Neuropathy – Pipeline by Abalone Bio Inc, 2022
- Table 17: Chemotherapy Induced Peripheral Neuropathy – Pipeline by Achelios Therapeutics Inc, 2022
- Table 18: Chemotherapy Induced Peripheral Neuropathy – Pipeline by Algenis, 2022
- Table 19: Chemotherapy Induced Peripheral Neuropathy – Pipeline by Algo Therapeutix SAS, 2022
- Table 20: Chemotherapy Induced Peripheral Neuropathy – Pipeline by Annji Pharmaceutical Co Ltd, 2022
- Table 21: Chemotherapy Induced Peripheral Neuropathy – Pipeline by Apexian Pharmaceuticals Inc, 2022
- Table 22: Chemotherapy Induced Peripheral Neuropathy – Pipeline by Aphios Corp, 2022
- Table 23: Chemotherapy Induced Peripheral Neuropathy – Pipeline by Aptinyx Inc, 2022
- Table 24: Chemotherapy Induced Peripheral Neuropathy – Pipeline by Asahi Kasei Pharma Corp, 2022
- Table 25: Chemotherapy Induced Peripheral Neuropathy – Pipeline by Avantyx Pharmaceuticals LLC, 2022
- Table 26: Chemotherapy Induced Peripheral Neuropathy – Pipeline by Bexion Pharmaceuticals LLC, 2022
- Table 27: Chemotherapy Induced Peripheral Neuropathy – Pipeline by Bright Minds Biosciences Inc, 2022
- Table 28: Chemotherapy Induced Peripheral Neuropathy – Pipeline by Bristol-Myers Squibb Co, 2022
- Table 29: Chemotherapy Induced Peripheral Neuropathy – Pipeline by Candel Therapeutics Inc, 2022
- Table 30: Chemotherapy Induced Peripheral Neuropathy – Pipeline by CSPC NBP Pharmaceutical Co Ltd, 2022
- Table 31: Chemotherapy Induced Peripheral Neuropathy – Pipeline by Daiichi Sankyo Co Ltd, 2022
- Table 32: Chemotherapy Induced Peripheral Neuropathy – Pipeline by Disarm Therapeutics Inc, 2022
- Table 33: Chemotherapy Induced Peripheral Neuropathy – Pipeline by EA Pharma Co Ltd, 2022
- Table 34: Chemotherapy Induced Peripheral Neuropathy – Pipeline by Egetis Therapeutics AB, 2022
- Table 35: Chemotherapy Induced Peripheral Neuropathy – Pipeline by Enveric Biosciences Inc, 2022
- Table 36: Chemotherapy Induced Peripheral Neuropathy – Pipeline by Exodos Life Sciences Limited Partnership, 2022
- Table 37: Chemotherapy Induced Peripheral Neuropathy – Pipeline by Helsinn Group, 2022
- Table 38: Chemotherapy Induced Peripheral Neuropathy – Pipeline by Hoba Therapeutics ApS, 2022
- Table 39: Chemotherapy Induced Peripheral Neuropathy – Pipeline by Immune Pharmaceuticals Inc, 2022
- Table 40: Chemotherapy Induced Peripheral Neuropathy – Pipeline by Kineta Inc, 2022
- Table 41: Chemotherapy Induced Peripheral Neuropathy – Pipeline by Kyorin Pharmaceutical Co Ltd, 2022
- Table 42: Chemotherapy Induced Peripheral Neuropathy – Pipeline by LTT Bio-Pharma Co Ltd, 2022
- Table 43: Chemotherapy Induced Peripheral Neuropathy – Pipeline by MAKScientific LLC, 2022
- Table 44: Chemotherapy Induced Peripheral Neuropathy – Pipeline by Medifron DBT Co Ltd, 2022
- Table 45: Chemotherapy Induced Peripheral Neuropathy – Pipeline by Metys Pharmaceuticals AG, 2022
- Table 46: Chemotherapy Induced Peripheral Neuropathy – Pipeline by Mundipharma International Ltd, 2022
- Table 47: Chemotherapy Induced Peripheral Neuropathy – Pipeline by Nanjing Aimeifei Biomedical Technology Co Ltd, 2022
- Table 48: Chemotherapy Induced Peripheral Neuropathy – Pipeline by NeurExo Sciences LLC, 2022
- Table 49: Chemotherapy Induced Peripheral Neuropathy – Pipeline by Neuropathix Inc, 2022
- Table 50: Chemotherapy Induced Peripheral Neuropathy – Pipeline by NeuroTherpia Inc, 2022
- Table 51: Chemotherapy Induced Peripheral Neuropathy – Pipeline by OliPass Corporation, 2022
- Table 52: Chemotherapy Induced Peripheral Neuropathy – Pipeline by Osmol Therapeutics Inc, 2022
- Table 53: Chemotherapy Induced Peripheral Neuropathy – Pipeline by Oxford Cannabinoid Technologies Ltd, 2022
- Table 54: Chemotherapy Induced Peripheral Neuropathy – Pipeline by PharmatrophiX Inc, 2022
- Table 55: Chemotherapy Induced Peripheral Neuropathy – Pipeline by Regulonix LLC, 2022
- Table 56: Chemotherapy Induced Peripheral Neuropathy – Pipeline by Resolute Pharma Inc, 2022
- Table 57: Chemotherapy Induced Peripheral Neuropathy – Pipeline by Senzer Ltd, 2022
- Table 58: Chemotherapy Induced Peripheral Neuropathy – Pipeline by SiteOne Therapeutics Inc, 2022
- Table 59: Chemotherapy Induced Peripheral Neuropathy – Pipeline by Skye Bioscience Inc, 2022
- Table 60: Chemotherapy Induced Peripheral Neuropathy – Pipeline by Sonnet BioTherapeutics Holdings Inc, 2022
- Table 61: Chemotherapy Induced Peripheral Neuropathy – Pipeline by Sova Pharmaceuticals Inc, 2022
- Table 62: Chemotherapy Induced Peripheral Neuropathy – Pipeline by Synerkine Pharma BV, 2022
- Table 63: Chemotherapy Induced Peripheral Neuropathy – Pipeline by Trevena Inc, 2022
- Table 64: Chemotherapy Induced Peripheral Neuropathy – Pipeline by WEX Pharmaceuticals Inc, 2022
- Table 65: Chemotherapy Induced Peripheral Neuropathy – Pipeline by Winsantor Inc, 2022
- Table 66: Chemotherapy Induced Peripheral Neuropathy – Pipeline by Xgene Pharmaceutical Inc, 2022
- Table 67: Chemotherapy Induced Peripheral Neuropathy – Dormant Projects, 2022
- Table 68: Chemotherapy Induced Peripheral Neuropathy – Dormant Projects, 2022 (Contd..1)
- Table 69: Chemotherapy Induced Peripheral Neuropathy – Dormant Projects, 2022 (Contd..2)
- Table 70: Chemotherapy Induced Peripheral Neuropathy – Discontinued Products, 2022
- List of Figures
- Figure 1: Number of Products under Development for Chemotherapy Induced Peripheral Neuropathy, 2022
- Figure 2: Number of Products under Development by Companies, 2022
- Figure 3: Number of Products under Development by Universities/Institutes, 2022
- Figure 4: Number of Products by Top 10 Targets, 2022
- Figure 5: Number of Products by Stage and Top 10 Targets, 2022
- Figure 6: Number of Products by Top 10 Mechanism of Actions, 2022
- Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Figure 8: Number of Products by Top 10 Routes of Administration, 2022
- Figure 9: Number of Products by Stage and Top 10 Routes of Administration, 2022
- Figure 10: Number of Products by Top 10 Molecule Types, 2022
- Figure 11: Number of Products by Stage and Top 10 Molecule Types, 2022
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.